Join Growin Stock Community!

Puretech health plcPRTC.US Overview

US StockHealthcare
(No presentation for PRTC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PRTC AI Insights

PRTC Overall Performance

PRTC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PRTC Recent Performance

2.21%

Puretech health plc

0.05%

Avg of Sector

-0.31%

S&P500

PRTC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PRTC Key Information

PRTC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PRTC Profile

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Price of PRTC

PRTC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PRTC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
7.88
PE Ratio (TTM)
9.86
Forward PE
-
PS Ratio (TTM)
63.42
PB Ratio
1.08
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
1066.67%
Net Margin
2366.10%
Revenue Growth (YoY)
1626.22%
Profit Growth (YoY)
313.08%
3-Year Revenue Growth
-16.95%
3-Year Profit Growth
346.21%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
7.88
PE Ratio (TTM)
9.86
Forward PE
-
PS Ratio (TTM)
63.42
PB Ratio
1.08
Price-to-FCF
-
Gross Margin
1066.67%
Net Margin
2366.10%
Revenue Growth (YoY)
1626.22%
Profit Growth (YoY)
313.08%
3-Year Revenue Growth
-16.95%
3-Year Profit Growth
346.21%

  • When is PRTC's latest earnings report released?

    The most recent financial report for Puretech health plc (PRTC) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PRTC's short-term business performance and financial health. For the latest updates on PRTC's earnings releases, visit this page regularly.

  • Where does PRTC fall in the P/E River chart?

    According to historical valuation range analysis, Puretech health plc (PRTC)'s current price-to-earnings (P/E) ratio is 8.23, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much debt does PRTC have?

    As of the end of the reporting period, Puretech health plc (PRTC) had total debt of 163.57M, with a debt ratio of 0.3. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does PRTC have?

    At the end of the period, Puretech health plc (PRTC) held Total Cash and Cash Equivalents of 260.6M, accounting for 0.47 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.